Clinical trials · Florida
Lymphoma clinical trials in Florida
We’re tracking 140 recruiting lymphoma studies with a site in Florida — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Florida
- NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Gainesville, FloridaAges 18 years+ - NCT07047885RecruitingPhase 1
Ropeginterferon for cutaneous T-cell lymphoma
This trial tests a medication called Ropeginterferon (a type of immune-supporting protein given as a shot) for people with different stages of cutaneous T-cell lymphoma. It may be an option if prior skin treatments haven't worked well enough.
Tampa, FloridaAges 18 years+ - NCT07015242RecruitingPhase 2
Liso-cel as first treatment for primary CNS lymphoma
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
Tampa, FloridaAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Lake Mary, FloridaAges 18 years+ - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Jacksonville, FloridaAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Weston, FloridaAges 18 years+ - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Jacksonville, FloridaAges 18 years+ - NCT06890884RecruitingPhase 2
Comparing two drug combos for untreated DLBCL
This trial tests a new drug, zilovertamab vedotin, added to standard chemo, compared with another approved drug combo for people with untreated DLBCL (a type of lymphoma). It aims to see which is more effective.
Boca Raton, FloridaAges 18 years+ - NCT06730542RecruitingPhase 1
Zanubrutinib plus pola-R-CHP and high-dose methotrexate for secondary CNS lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
Miami, FloridaAges 18 years+ - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Miami, FloridaAges 18 years+ - NCT06569680RecruitingPhase 2
Mosunetuzumab for untreated extranodal marginal zone lymphoma
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Miami, FloridaAges 18 years+ - NCT06549595RecruitingPhase 3
Testing a new drug combo for untreated follicular lymphoma
This study tests a new combination of two drugs (surovatamig and rituximab) for people with follicular lymphoma who have not been treated before. The goal is to see if this combination works better than standard treatments.
Jacksonville, FloridaAges 18–130 - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
Tampa, FloridaAges 18 years+ - NCT06514794RecruitingPhase 2
A study of a new cell therapy for T-cell acute lymphoblastic leukemia and lymphoma
This trial tests an investigational cell therapy that uses donated immune cells to find and destroy cancer cells in patients with T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to treatment. The goal is to see if this therapy can help achieve remission for these patients.
Tampa, FloridaAges 6 months+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
St. Petersburg, FloridaAges 6 months–25 years - NCT06377566RecruitingPhase 2
BV-AVD for bulky Hodgkin lymphoma
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
Miami, FloridaAges 18 years+ - NCT06136559RecruitingPhase 3
Study of Nemtabrutinib vs ibrutinib or acalabrutinib for untreated CLL/SLL
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
Boca Raton, FloridaAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Coral Gables, FloridaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Jacksonville, FloridaAges 18 years+ - NCT06029309RecruitingPhase 1/Phase 2
Zanubrutinib and tafasitamab for mantle cell lymphoma
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Miami, FloridaAges 18 years+ - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT05705531Recruiting
Cardiac MRI study of heart health after Hodgkin lymphoma treatment
This study looks at how certain blood-related “growth patterns” connect to long-term heart health after treatment for classical Hodgkin lymphoma. It may help doctors better predict who could develop heart problems and how to monitor them over time.
Orlando, FloridaAges 7 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Fort Lauderdale, FloridaAges 5–60
Lymphoma trials by city in Florida
Where these studies are running in Florida
Institutions with a site for the recruiting lymphoma studies listed above.
- University of Miami · 5 studies
- Moffitt Cancer Center · 4 studies
- Mayo Clinic Florida · 3 studies
- Arnold Palmer Hospital for Children · 2 studies
- Golisano Children's Hospital of Southwest Florida · 2 studies
- Johns Hopkins All Children's Hospital · 2 studies
- Lynn Cancer Institute at Baptist Health · 2 studies
- Mount Sinai Medical Center · 2 studies
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lymphoma trials in other states
Common questions
- Are there lymphoma clinical trials in Florida?
- Yes. We're currently tracking 140 recruiting lymphoma studies with a site in Florida, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study in Florida?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Florida to take part?
- Not necessarily. These studies have a site in Florida, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open in Florida regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.